이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Innate Pharma 관리

관리 기준 확인 4/4

Innate Pharma's CEO는 Herve Brailly, Jan1999 에 임명되었습니다 의 임기는 25.42 년입니다. 는 € 1.54M 가치에 해당하는 회사 주식의 0.92% 직접 소유합니다. 1.54M. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 5.6 년입니다.

주요 정보

Herve Brailly

최고 경영자

€100.0k

총 보상

CEO 급여 비율	n/a
CEO 임기	25.5yrs
CEO 소유권	0.9%
경영진 평균 재임 기간	4.4yrs
이사회 평균 재임 기간	5.7yrs

최근 관리 업데이트

Recent updates

CEO

Herve Brailly (63 yo)

25.5yrs

테뉴어

€100,000

보상

Dr. Herve Brailly, Ph.D. Co-Founded Innate Pharma S.A in 1999 and served as its Chairman of Supervisory Board since December 31, 2016 until January 1, 2024 and serves as its Interim CEO and Chairman of the...

리더십 팀

이름	위치	테뉴어	보상	소유권
Herve Brailly	Co-Founder	25.5yrs	€100.00k	0.91% € 1.5m
Yannis Morel	Executive VP	9.2yrs	€599.92k	0.24% € 384.5k
François Romagné	Founder	no data	데이터 없음	데이터 없음
Eric Vivier	Founder	6.5yrs	데이터 없음	0.26% € 416.2k
Marc Bonneville	Founder	no data	데이터 없음	데이터 없음
Jean Fournié	Founder	no data	데이터 없음	데이터 없음
Alessandro Moretta	Founder	no data	데이터 없음	데이터 없음
Frederic Lombard	Senior VP & CFO	3.3yrs	데이터 없음	0.014% € 22.5k
Sonia Quaratino	Executive VP	less than a year	데이터 없음	데이터 없음
Arvind Sood	Executive VP	less than a year	데이터 없음	데이터 없음
Henry Wheeler	Vice President of Investor Relations & Communication	1.5yrs	데이터 없음	0.0039% € 6.3k
Odile Belzunce	Vice President of Compliance & Operations	5.5yrs	데이터 없음	0.077% € 123.3k

4.4yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: IDDA 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mario Sznol	Strategic Advisory Board Member	5.7yrs	데이터 없음	데이터 없음
Olivier Martinez	Member of Supervisory Board	no data	데이터 없음	데이터 없음
Ruslan Medzhitov	Strategic Advisory Board Member	5.7yrs	데이터 없음	데이터 없음
Gilles Brisson	Independent Member of Supervisory Board	17.1yrs	€29.00k	0.090% € 144.7k
Jean-Yves Blay	Independent Member of Supervisory Board	6.6yrs	€29.00k	0.000060% € 96.2
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	15.1yrs	€42.00k	0.031% € 49.7k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	4.2yrs	€60.00k	0.0012% € 2.0k
Miriam Merad	Chairman of Strategic Advisory Board	5.7yrs	데이터 없음	데이터 없음
Veronique Chabernaud	Independent Member of Supervisory Board	9.3yrs	€48.00k	0.00082% € 1.3k
Sebastian Amigorena	Strategic Advisory Board Member	5.7yrs	데이터 없음	데이터 없음
Aurelien Marabelle	Strategic Advisory Board Member	5.7yrs	데이터 없음	데이터 없음
Tanguy Seiwert	Strategic Advisory Board Member	5.7yrs	데이터 없음	데이터 없음

5.7yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: IDDA 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.

Innate Pharma 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Recent updates

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령